138
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Evaluation of the embolic effect and degradability of gelatin microspheres and gelpart particles

, , , , , , , , , , & show all
Pages 157-164 | Received 01 May 2012, Accepted 20 Jul 2012, Published online: 28 Aug 2012

References

  • Tadavarthy SM, Moller JH, Amplatz K. Polyvinyl alcohol (Ivalon)–a new embolic material. Am J Roentgenol Radium Ther Nucl Med. 1975;125:609–16.
  • Castaneda-Zuniga WR, Lehnert M, Nath PH, Zollikofer C, Velasquez G, Amplatz K. Therapeutic embolization of facial arteriovenous fistulae. Radiology. 1979;132:599–602.
  • Coldwell DM, Stokes KR, Yakes WF. Embolotherapy: agents, clinical applications, and techniques. Radiographics. 1994;14:623–43.
  • Sone M, Arai Y, Shimizu T, Takeuchi Y, Higashihara H, Ohgi S, et al. Phase I/II multiinstitutional study of uterine artery embolization with gelatin sponge for symptomatic uterine leiomyomata: Japan Interventional Radiology in Oncology Study Group study. J Vasc Interv Radiol. 2010;21:1665–71.
  • Hahn S, Kim YJ, Kwon W, Cha SW, Lee WY. Comparison of the effectiveness of embolic agents for bronchial artery embolization: gelfoam versus polyvinyl alcohol. Korean J Radiol. 2010;11:542–6.
  • Ryu RK, Omary RA, Sichlau MJ, Siddiqi A, Chrisman HB, Nemcek AA, et al. Comparison of pain after uterine artery embolization using tris-acryl gelatin microspheres versus polyvinyl alcohol particles. Cardiovasc Intervent Radiol. 2003;26:375–8.
  • Katsumori T, Kasahara T, Oda M, Kotani T. Initial experience of uterine fibroid embolization using porous gelatin sponge particles. Cardiovasc Intervent Radiol. 2011;34:513–21.
  • Malagari K, Pomoni M, Spyridopoulos TN, Moschouris H, Kelekis A, Dourakis S, et al. Safety profile of sequential transcatheter chemoembolization with DC Bead: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol. 2011;34:774–85.
  • Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol. 2011;197:W562–770.
  • Ohta S, Nitta N, Sonoda A, Seko A, Tanaka T, Takahashi M, et al. Cisplatin-conjugated Gelpart: initial study in vitro. Hepatol Res. 2008;38:1050–3.
  • Sone M, Osuga K, Shimazu K, Higashihara H, Nakazawa T, Kato K, et al. Porous gelatin particles for uterine artery embolization: an experimental study of intra-arterial distribution, uterine necrosis, and inflammation in a porcine model. Cardiovasc Intervent Radiol. 2010;33:1001–8.
  • Tabata Y, Ikada Y. Synthesis of gelatin microspheres containing interferon. Pharm Res. 1989;6:422–7.
  • Ohta S, Nitta N, Takahashi M, Murata K, Tabata Y. Degradable gelatin microspheres as an embolic agent: an experimental study in a rabbit renal model. Korean J Radiol. 2007;8:418–28.
  • Ohta S, Nitta N, Sonoda A, Seko A, Tanaka T, Takahashi M, et al. Cisplatin-conjugated degradable gelatin microspheres: fundamental study in vitro. Br J Radiol. 2009;82:380–5.
  • Ohta S, Nitta N, Sonoda A, Seko A, Tanaka T, Takahashi M, et al. Prolonged local persistence of cisplatin-loaded gelatin microspheres and their chemoembolic anti-cancer effect in rabbits. Eur J Radiol. 2009;72:534–40.
  • Toyama T, Nitta N, Ohta S, Tanaka T, Nagatani Y, Takahashi M, et al. Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma. Jpn J Radiol. 2012;30:62–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.